Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

United Therapeutics (UTHR) Invested Capital (2016 - 2025)

Historic Invested Capital for United Therapeutics (UTHR) over the last 17 years, with Q3 2025 value amounting to $6.6 billion.

  • United Therapeutics' Invested Capital rose 137.37% to $6.6 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $6.6 billion, marking a year-over-year increase of 137.37%. This contributed to the annual value of $6.7 billion for FY2024, which is 562.59% up from last year.
  • Latest data reveals that United Therapeutics reported Invested Capital of $6.6 billion as of Q3 2025, which was up 137.37% from $7.2 billion recorded in Q2 2025.
  • United Therapeutics' Invested Capital's 5-year high stood at $7.2 billion during Q2 2025, with a 5-year trough of $3.4 billion in Q1 2021.
  • Over the past 5 years, United Therapeutics' median Invested Capital value was $5.4 billion (recorded in 2023), while the average stood at $5.3 billion.
  • Its Invested Capital has fluctuated over the past 5 years, first skyrocketed by 3310.82% in 2023, then surged by 137.37% in 2025.
  • Quarter analysis of 5 years shows United Therapeutics' Invested Capital stood at $4.0 billion in 2021, then increased by 21.16% to $4.8 billion in 2022, then soared by 33.11% to $6.4 billion in 2023, then grew by 5.63% to $6.7 billion in 2024, then dropped by 2.28% to $6.6 billion in 2025.
  • Its last three reported values are $6.6 billion in Q3 2025, $7.2 billion for Q2 2025, and $7.0 billion during Q1 2025.